Contineum Therapeutics, Inc.
CTNM
$11.01
$0.575.46%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 2.52% | -1.75% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.59% | -1.15% | |||
| Operating Income | 16.59% | 1.15% | |||
| Income Before Tax | 20.25% | -0.31% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 20.25% | -0.31% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 20.25% | -0.31% | |||
| EBIT | 16.59% | 1.15% | |||
| EBITDA | 16.68% | 1.16% | |||
| EPS Basic | 26.54% | -0.21% | |||
| Normalized Basic EPS | 26.53% | -0.21% | |||
| EPS Diluted | 26.54% | -0.21% | |||
| Normalized Diluted EPS | 26.53% | -0.21% | |||
| Average Basic Shares Outstanding | 8.57% | 0.10% | |||
| Average Diluted Shares Outstanding | 8.57% | 0.10% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||